Naivek, Success in Research on Gene Drug Delivery System 'Inhibition of Disease-Causing Genes'

[Asia Economy Reporter Hyungsoo Park] Naivek announced on the 21st that it has succeeded in the research of delivery systems and fusion proteins as the first achievement related to the gene drug delivery system jointly developed with Daiichi Sankyo.

Naivek started research after receiving gene drug candidate substances from Daiichi Sankyo following a formal kickoff meeting with Daiichi Sankyo in November last year. Excellent research results were confirmed in in vitro tests. Naivek's drug delivery platform ‘NIPEP-TPP’ successfully fused with Daiichi Sankyo's candidate substances. Intracellular stability and efficacy verification were also completed.

Naivek will conduct its own preliminary animal tests as the second research phase. The second research results report will be finalized around May to June. The second research results report, along with the improved gene substances applied with NIPEP-TPP, will be delivered to Daiichi Sankyo.

A Naivek official said, "The joint research and development of the gene drug delivery system with Daiichi Sankyo is progressing smoothly," and "we have derived results superior to the first target indicators."

He added, "The gene fusion protein research is a new concept of delivery system that breaks away from the existing lipid nanoparticles (LNP)," and "based on the research results, we expect to produce research outcomes through various future studies."

In October last year, Naivek has been researching to apply the ‘mRNA, siRNA fusion gene delivery system’ among the self-developed targeted tissue penetration ‘NIPEP-TPP drug delivery system’ to develop new drugs. Naivek's drug delivery platform NIPEP-TPP has an effective function that selectively penetrates the target tissue with TPP peptides and stably binds siRNA to prevent degradation in the body.

This content was produced with the assistance of AI translation services.